About Arocell

AroCell is a Swedish diagnostics company with the vision to improve the monitoring of oncological and bacterial diseases. We have a broad product portfolio of IVD tests that deliver high-value clinical information for the detection of disease with indications spanning everything from urological cancers to typhoid fever. AroCell targets different patient groups in different parts of the world.

Based on our proprietary technologies and our biomarkers, we develop tests that are clinically useful and economically viable, making us a valuable and relevant diagnostic partner for healthcare professionals. We provide rapid tests, laboratory tests and platform tests that improve decision making and are non-invasive, cost effective, and easy to perform – all of which are important criteria for the healthcare and payer community.

At AroCell, we are proud that our diagnostic solutions can contribute to one of the ‘three imperatives’ for reducing the burden of disease: diagnostics, therapeutics and vaccines. In the wake of covid-19, it is fair to say that diagnostics has been given a well-deserved place in the healthcare limelight. With a growing number of elderly people around the world in combination with an increase in the incidence of chronic diseases, the need for accurate diagnostics is essential.

We create value for our shareholders by executing our strategy of increasing sales volumes in existing markets, obtaining market approvals in other prioritized markets, and continuously developing the next generation of IVD tests. With a pipeline that meets current and future demands, we stay relevant not only to patients, but to all our stakeholders. AroCell was first listed in 2016 and our shares are traded on Stockholm Nasdaq First North.

With an organization that occupies the entire value chain from R&D to manufacturing and marketing, we have the flexibility of a small company and the characteristics of a big company. It enables us to be a fast mover in the fast growing field of IVD-tests This is critical for us to be able deliver on our vision to be valuable and relevant diagnostic partner in oncology healthcare.